Study Says Drug Could Hamper Bone Growth
Posted on: Thursday, 11 November 2004, 18:00 CST
A common class of drugs prescribed to children with depression may have an adverse effect on bone growth, a study says.
Researchers at the Indiana University School of Medicine said they looked at the effect of selective serotonin-reuptake inhibitors, or SSRIs, on bone accrual in growing mice. The findings showed a reduction in bone mass and size in the mice administered an SSRI.
The study was outlined in the journal Endocrinology.
These findings indicate a potential negative impact of SSRIs on the skeleton and point to a need for further research into the prescribing of these drugs to children and adolescents, said lead author Stuart J. Warden, assistant professor in the I.U. Department of Physical Therapy.
The study investigated the effects of fluoxetine, commonly known as Prozac, on bone growth in young mice. Warden and his colleagues selected fluoxetine because it is the only prescription antidepressant currently approved by the FDA for children and adolescents.
Source: United Press International
Related Articles
- YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
- Gluten-Free Diet Reduces Bone Problems In Children With Celiac Disease
- Incorrect Treatment Of Bone Fractures In Children
- Researchers Study How Children View And Treat Their Peers With Undesirable Characteristics
- Fat tissue stimulates bone growth in children
- Scrapping Plans for Health Study Hurts Children
- VivoMetrics Lifeshirt System Used in Study Involving Children and Parents Affected By 9/11
- Calcium, Dairy Products, and Bone Health in Children and Young Adults
- Children's Adaptations to a Fat-Reduced Diet: The Dietary Intervention Study in Children (DISC)
- National Study on Children's Health to Provide Wealth of Information
 |
 |
User Comments (0)
RSS Feeds